m6A modification is reversible, achieved by proteins known as m6A “writers,” “erasers,” and “readers.” Recent studies have shown that aberrant m6A levels caused by methyltransferase-like 3 (METTL3) are involved in the development and progression of numerous malignancies [e.g., lung cancer and acute myeloid leukemia (AML)], inflammatory diseases, metabolic disorders, and cardiovascular diseases [11–13]. Here, METTL3 is linked to cardiovascular disorder.